CA2817249C — Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof

USPTO Abstract

Crystalline polymorphs of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid: (see above formula) are described. These crystalline polymorphs are characterized by peaks at 10.32, 18.84 and 20.75 °2.theta.~0.1°2.theta. or by peaks at 10.46, 18.76, and 19.83 °2.theta.~0.1°2.theta.. 2-(5-bromo-4-(4-cyclopropylnaphthalen-l-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid is known to decrease uric acid levels. The crystalline polymorphs of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate may exhibit increased stability in comparison to the amorphous solid state form of the carboxylic acid. Pharmaceutical compositions comprising the crystalline polymorphs are also described as well as use of the crystalline polymorphs for treating or preventing hyperuricemia or a disease caused by elevated uric acid levels and for use in treating or preventing gout.